skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SU-F-T-653: Radiation Exposure from Cs-131 Permanent Seed Implants

Abstract

Purpose: Permanent seed implants have traditionally been used to treat prostate, lung and head or neck cancers using I-125 and Pd-103. Cs-131, which has higher dose rate is being used to treat brain, head and/or neck cancers in our clinic, therefore, we chose to monitor the dose received by surgeons during the extensive procedure. The aims of this work are to assess the level of radiation exposure to surgeons and the instantaneous exposure at bedside and 1 m from patients. Methods: Ten patients received Cs-131 implants for recurrent brain,head and/or neck cancer; the median implanted activity, number of implanted seeds and prescription dose at 0.5 cm from the perpendicular plane of the implant were: 54.3 mCi (14.52 – 77); 19 (4 – 24) and 60 Gy (range 42 – 60) respectively. Radiation exposure was recorded at bedside and 1 m from the patient using Victoreen ion chamber (Fluke Biomedical, Cleveland, OH). Exposure to surgeons was measured using TLD (Mirion Technologies (GDS), Inc., USA). Results: The median equivalent dose rate at 1 m and bedside immediately following implantation were 1.49×10-2 mSv/h (8.77×10-3–2.63×10-2) and 7.76×10-2 mSv/h (3.1×10-2– 1.53×10-1) respectively. Median equivalent dose to surgeons’ hands was 0.60 mSv (0.33 – 1.48) andmore » no doses were detected for whole-body. Surgical reconstruction for one patient was performed 71 days post-implant and resulted in zero exposure to surgeons. Conclusion: The recorded exposure rates were low when compared with the literature. Post procedure surveys at bed site and 1 m indicated that all patients were within safe limits for discharge (< 0.05 mSv/h at 1 m). However, as a precautionary measure, patients were advised to avoid direct contact with children and pregnant women within four weeks of the implant and stay at least at 3 ft from other people. Surgeons doses were well within occupational dose limits.« less

Authors:
; ; ; ; ; ; ; ; ;  [1]
  1. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (United States)
Publication Date:
OSTI Identifier:
22649208
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; BRACHYTHERAPY; DOSE EQUIVALENTS; DOSE LIMITS; DOSE RATES; GY RANGE 10-100; HEAD; IODINE 125; IONIZATION CHAMBERS; IONS; NECK; NEOPLASMS; PATIENTS; RADIATION SOURCE IMPLANTS; RATS

Citation Formats

Giaddui, T, Hardin, M, To, D, Kremmel, E, Peng, C, Hann, P, Richardson, S, Yu, Y, Harrison, A, and Doyle, L. SU-F-T-653: Radiation Exposure from Cs-131 Permanent Seed Implants. United States: N. p., 2016. Web. doi:10.1118/1.4956838.
Giaddui, T, Hardin, M, To, D, Kremmel, E, Peng, C, Hann, P, Richardson, S, Yu, Y, Harrison, A, & Doyle, L. SU-F-T-653: Radiation Exposure from Cs-131 Permanent Seed Implants. United States. doi:10.1118/1.4956838.
Giaddui, T, Hardin, M, To, D, Kremmel, E, Peng, C, Hann, P, Richardson, S, Yu, Y, Harrison, A, and Doyle, L. Wed . "SU-F-T-653: Radiation Exposure from Cs-131 Permanent Seed Implants". United States. doi:10.1118/1.4956838.
@article{osti_22649208,
title = {SU-F-T-653: Radiation Exposure from Cs-131 Permanent Seed Implants},
author = {Giaddui, T and Hardin, M and To, D and Kremmel, E and Peng, C and Hann, P and Richardson, S and Yu, Y and Harrison, A and Doyle, L},
abstractNote = {Purpose: Permanent seed implants have traditionally been used to treat prostate, lung and head or neck cancers using I-125 and Pd-103. Cs-131, which has higher dose rate is being used to treat brain, head and/or neck cancers in our clinic, therefore, we chose to monitor the dose received by surgeons during the extensive procedure. The aims of this work are to assess the level of radiation exposure to surgeons and the instantaneous exposure at bedside and 1 m from patients. Methods: Ten patients received Cs-131 implants for recurrent brain,head and/or neck cancer; the median implanted activity, number of implanted seeds and prescription dose at 0.5 cm from the perpendicular plane of the implant were: 54.3 mCi (14.52 – 77); 19 (4 – 24) and 60 Gy (range 42 – 60) respectively. Radiation exposure was recorded at bedside and 1 m from the patient using Victoreen ion chamber (Fluke Biomedical, Cleveland, OH). Exposure to surgeons was measured using TLD (Mirion Technologies (GDS), Inc., USA). Results: The median equivalent dose rate at 1 m and bedside immediately following implantation were 1.49×10-2 mSv/h (8.77×10-3–2.63×10-2) and 7.76×10-2 mSv/h (3.1×10-2– 1.53×10-1) respectively. Median equivalent dose to surgeons’ hands was 0.60 mSv (0.33 – 1.48) and no doses were detected for whole-body. Surgical reconstruction for one patient was performed 71 days post-implant and resulted in zero exposure to surgeons. Conclusion: The recorded exposure rates were low when compared with the literature. Post procedure surveys at bed site and 1 m indicated that all patients were within safe limits for discharge (< 0.05 mSv/h at 1 m). However, as a precautionary measure, patients were advised to avoid direct contact with children and pregnant women within four weeks of the implant and stay at least at 3 ft from other people. Surgeons doses were well within occupational dose limits.},
doi = {10.1118/1.4956838},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}